Uncategorized
3-year outcomes similar in vitrectomized, non-vitrectomized eyes after ranibizumab treatment for DME
BOSTON — Vitrectomized eyes fared as well as non-vitrectomized eyes after treatment with ranibizumab for diabetic macular edema, according to a study presented at Macula 2015.“The efficacy of ranibizumab in the treatment of diabetic retinopathy is well established, but there remain some uncertainties in clinical management with ranibizumab for DME,” Jack Wells, MD,said. “There’s a common clinical impression that the duration of action of anti-VEGF injected in eyes with prior vitrectomy would be shorter than in eyes without prior vitrectomy due to more rapid clearing of the drug, and therefore (Read more...)